Re-personalization and stratification of hemophilia care in an evolving treatment landscape.
View/ Open
Volume
24
Pagination
737 - 741
Publisher
DOI
10.1080/16078454.2019.1687798
Journal
Hematology
Issue
ISSN
1024-5332
Metadata
Show full item recordAbstract
Hemophilia therapeutics are evolving rapidly. Comprehensive care must also evolve to embrace this change. Online tools and guidelines are widely available to optimize prophylaxis with conventional clotting factor concentrates using an individual's predicted pharmacokinetic profile. Novel hemostatic agents (e.g. biphenotypic antibody) are also becoming widely available, with other agents with differing mechanisms of action in final stages of trial. Contemporary issues including challenges of prophylaxis; bleed treatment; laboratory monitoring and inhibitor risk/surveillance are summarized in this narrative review, focusing on how a re-personalization of education and treatment will be necessary to meet these challenges of the rapidly changing therapeutic landscape.
Authors
Hart, DP; Kessler, CM; Aledort, LCollections
- Centre for Immunobiology [1121]
Language
Licence information
Copyright statements
The following license files are associated with this item: